Pravin Ghadge

Sun Pharma (India) — India

Medicine · Health Sciences

3h-index34citations13works0.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(5), Metabolism, Diabetes, and Cancer(3), Diabetes Management and Research(2), Gastroesophageal reflux and treatments(2), Natural Antidiabetic Agents Studies(2)

Publications13 total

1150: FEXUPRAZAN, A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER VS. ESOMEPRAZOLE IN INDIAN PATIENTS WITH EROSIVE ESOPHAGITIS: A PHASE 3, MULTICENTRE, RANDOMIZED, ACTIVE-CONTROLLED STUDY
Gastroenterology·2025
Fixed dose combination of dapagliflozin, glimepiride and extended‐release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase <scp>III</scp> , open label, randomized clinical study in India
Diabetes Obesity and Metabolism·2025· 5 citedOpen Access
Author response for "Fixed dose combination of dapagliflozin, glimepiride and extended‐release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase &lt;scp&gt;III&lt;/scp&gt;, open label, randomized clinical study in India"
2025
Author response for "Fixed dose combination of dapagliflozin, glimepiride and extended‐release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase &lt;scp&gt;III&lt;/scp&gt;, open label, randomized clinical study in India"
2024
Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients with HbA1c 9%-11%
Endocrine Abstracts·2024
Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients aged &lt;45 years and 45 to 65 years
Endocrine Abstracts·2024
The Efficacy and Safety of High Dose (10 mg) of Desloratadine (Dazit® 10) in the Treatment of Chronic Spontaneous Urticaria in India: A Phase III, Multicentric, Open-Label, Single-Arm Study
Cureus·2024Open Access
S512 Effect of Esomeprazole Dual Release Gastro-Resistant Tablets in Patients With Refractory Gastroesophageal Reflux Disease in Comparison to Esomeprazole Tablets: A Double-Blind Randomized, Phase 3 Active-Controlled Trial
The American Journal of Gastroenterology·2023
Diagnostic accuracy and complications of image-guided core needle biopsy of lung lesions
Clinical Radiology·2022
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)
Expert Opinion on Biological Therapy·2022· 1 cited
Evaluation of Efficacy and Safety of ‘AHPL/AYTOP/2014A’ in Patients Suffering from Aphthous Ulcers - An Open Label, Randomized, Multi-center, Prospective, Active Controlled, Parallel Group, Clinical Study
International Journal of Pharmaceutical Investigation·2021Open Access
Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration
Clinical ophthalmology·2021· 18 citedOpen Access
Randomized Comparative Clinical Study of First Global Omalizumab Biosimilar with Innovator Product in Moderate to Severe Persistent Asthma.
PubMed·2020· 10 cited

Frequent Co-authors

Suyog Mehta(8), Mandodari Rajurkar(6), Piyush M. Patel(6), Dipak D. Patil(6), Lalit Lakhwani(6), Dinesh Gangwani(5), Manish Singh(5), Sandeep K. Gupta(5), Prakash Kurmi(5), Jayesh Ambaliya(5), Nilesh Lomte(5), Sandip Gofne(5), Shruti Saha(4), Rakesh Sahay(3), Narendra Kale(3), Manoj Srivastava(3), Saurabh Agarwal(3), Priyanka Kashid(3), Vikas Agarwal(3), Pradeep Rai(3)